ClinicalTrials.gg
CompletedNCT04809220AWARD-JPNUpdated May 22, 2024Results posted

A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes

A Phase 3 interventional study of Dulaglutide and Oral antihyperglycemics in Diabetes Mellitus, Diabetes Mellitus, Type 2 and Glucose Metabolism Disorders, sponsored by Eli Lilly and Company. Completed at 44 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-05-22.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
591
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.

Enrollment
14th of 54
591 · median 159
Started
2021
the only one that year
Phase 3
22 of 54
1 open now
Registered
41st of 54
by date
Lead sponsor
43 of 54
Eli Lilly and Company

Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 14th largest by enrollment, is the only one that started in 2021, is one of 22 in phase 3, and was the 41st registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About dulaglutide

dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of 2 doses of dulaglutide in Japanese participants with type 2 diabetes. The study duration is approximately 58 weeks.

03

Conditions studied

  • Diabetes Mellitus
  • Diabetes Mellitus, Type 2
  • Glucose Metabolism Disorders
  • Metabolic Disease
  • Endocrine System Diseases
  • Hypoglycemic Agents
  • Type 2 Diabetes Mellitus (T2DM)
04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 591 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with type 2 diabetes (T2D) ≥ 6 months according to the World Health Organization (WHO) classification.
  • Treated with stable doses of a single OAM for at least 8 weeks prior to screening; the dose must be more than or equal to minimum maintenance dose.
  • Have the following result at screening.

    • Participants taking DPP-4i: ≥7.5% and ≤9.5%,
    • Participants taking another OAM: ≥8.0% and ≤10.0%
  • Stable body weight for at least 8 weeks prior to screening or not changed by more than 5 % in the past 8 weeks
  • Have a (BMI) ≥18.5 kilogram/square meter (kg/m²) and \<35 kg/m² at Day 1.

Exclusion criteria

Exclusion Criteria:

  • Have type 1 diabetes (T1D)
  • Have a history of ≥1 episode of ketoacidosis or hyperosmolar state/coma
  • Have had any myocardial infarction (MI), heart failure or cerebrovascular accident (stroke)
  • Have a known gastric empty abnormality
  • Have acute or chronic hepatitis
  • Have had chronic or acute pancreatitis
  • Have any self or family history of type 2A or type 2B multiple endocrine neoplasia in the absence of known C-cell hyperplasia
  • Have any self or family history of medullary C-cell hyperplasia, focal hyperplasia, or carcinoma (including sporadic, familial, or part of Multiple endocrine neoplasia (MEN) 2A or 2B syndrome)
  • Have evidence of significant, active abnormality
  • Have evidence of significant, uncontrolled endocrine abnormality
  • Have active or untreated , or have been in remission from clinically significant malignancy (other than basal cell or squamous cell skin cancer) for less than 5 years
  • Have any hematologic condition that may interfere with measurement
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
591 participants (actual)

Study arms

  • Experimental
    Dulaglutide 1.5 milligram (mg)

    Participants received 1.5 mg of dulaglutide given weekly subcutaneously (SC) during the 52-week treatment period. Dulaglutide will be given alone or in combination with 1 oral antihyperglycemic medication (OAM). Participants on dipeptidyl peptidase-4 inhibitors (DPP-4i) discontinued DPP-4i at randomization and was regarded as monotherapy of dulaglutide, other OAMs continued at same dose during study period and were regarded as combination therapy with dulaglutide.

    Drug: Dulaglutide · Drug: Oral antihyperglycemics

  • Active comparator
    Dulaglutide 0.75 mg

    Participants received 0.75 mg of dulaglutide given weekly SC during the 52-week treatment period. Dulaglutide will be given alone or in combination with 1 OAM. Participants on DPP-4i discontinued DPP-4i at randomization and was regarded as monotherapy of dulaglutide, other OAMs continued at same dose during study period and were regarded as combination therapy with dulaglutide.

    Drug: Dulaglutide · Drug: Oral antihyperglycemics

Interventions

07

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26

    HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed model repeated measures (MMRM) model with Baseline + Pre-study oral antihyperglycemic medication (OAM) Group 1 + Treatment + Time + Treatment × Time as variables.

    Time frame: Baseline, Week 26

Secondary outcomes

  1. Change From Baseline in HbA1c at Week 52

    HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time. LS mean was determined by MMRM model with Baseline + Pre-study OAM Group 1 + Treatment + Time + Treatment × Time as variables.

    Time frame: Baseline, Week 52

  2. Percentage of Participants Achieving HbA1c Target ≤6.5% and <7.0%

    HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time. The odds ratios, confidence intervals, and p-values were determined by generalized linear mixed model (GLM) with Baseline + Pre-study OAM Group 1 + Treatment + Time + Treatment × Time as variables.

    Time frame: Week 52

  3. Change From Baseline in Fasting Serum Glucose (FSG)

    FSG is a test to determine sugar levels in serum sample after an overnight fast. LS mean was determined by MMRM model with Baseline + Baseline HbA1c (High, Low) Group, OAM-based + Pre-study OAM Group 1 + Treatment + Time + Treatment\*Time as variables.

    Time frame: Baseline, Week 52

  4. Change From Baseline in 6-point Self-Monitored Blood Glucose (SMBG)

    SMBG 6-point profiles were measured at morning (premeal-fasting, 2-hour post meal), midday (premeal, 2-hour post meal), and evening (premeal, 2-hour post meal). LS mean was determined by analysis of covariance (ANCOVA) model with Baseline + Baseline HbA1c (High, Low) Group, OAM-based + Pre-study OAM Group 1 + Treatment as variables.

    Time frame: Baseline, Week 26

  5. Change From Baseline in Body Weight

    LS mean was determined by MMRM model with Baseline + Baseline HbA1c (High, Low) Group, OAM-based + Pre-study OAM Group 1 + Treatment + Time + Treatment\*Time as variables.

    Time frame: Baseline, Week 52

08

Results

Posted Sep 21, 2023

Participant flow

591 participants were randomized in the study. However, due to good clinical practice (GCP) compliance issues identified at one of the investigative sites, all 5 participants from that site were excluded from the study analyses.

Participant flow — Overall Study
MilestoneDulaglutide 1.5 Milligram (mg)Dulaglutide 0.75 mg
Started395196
Exposed to at least 1 dose of study intervention (excluding the gcp compliance investigative site)391195
Completed377190
Not completed186
Withdrew: Adverse event40
Withdrew: Death10
Withdrew: Lost to follow-up30
Withdrew: Physician decision01
Withdrew: Withdrawal by subject95
Withdrew: Due to long-term overseas business trips10

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1c (HbA1c) at Week 26

HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed model repeated measures (MMRM) model with Baseline + Pre-study oral antihyperglycemic medication (OAM) Group 1 + Treatment + Time + Treatment × Time as variables.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · Percentage of HbA1c
Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26
Percentage of HbA1cDulaglutide 1.5 mgDulaglutide 0.75 mg
Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26-1.53 ± 0.043-1.25 ± 0.060
Statistical analysis
  • Dulaglutide 1.5 mg vs Dulaglutide 0.75 mg · Mixed Models Analysis · p = <.001 · Ls mean difference: -0.29 · 95% CI -0.43 to -0.14
SecondaryChange From Baseline in HbA1c at Week 52

HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time. LS mean was determined by MMRM model with Baseline + Pre-study OAM Group 1 + Treatment + Time + Treatment × Time as variables.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Percentage of HbA1c
Change From Baseline in HbA1c at Week 52
Percentage of HbA1cDulaglutide 1.5 mgDulaglutide 0.75 mg
Change From Baseline in HbA1c at Week 52-1.50 ± 0.046-1.19 ± 0.065
Statistical analysis
  • Dulaglutide 1.5 mg vs Dulaglutide 0.75 mg · Mixed Models Analysis · p = <.001 · Ls mean difference: -0.31 · 95% CI -0.47 to -0.15
SecondaryPercentage of Participants Achieving HbA1c Target ≤6.5% and <7.0%

HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time. The odds ratios, confidence intervals, and p-values were determined by generalized linear mixed model (GLM) with Baseline + Pre-study OAM Group 1 + Treatment + Time + Treatment × Time as variables.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving HbA1c Target ≤6.5% and <7.0%
Percentage of participantsDulaglutide 1.5 mgDulaglutide 0.75 mg
HbA1c ≤ 6.5%22.8821.26
HbA1c < 7%46.3338.51
Statistical analysis
  • Dulaglutide 1.5 mg vs Dulaglutide 0.75 mg · Generalized Linear Mixed Model (GLM) · p = 0.560 · Odds ratio (or): 1.15 · 95% CI 0.71 to 1.87
  • Dulaglutide 1.5 mg vs Dulaglutide 0.75 mg · Generalized Linear Mixed Model (GLM) · p = 0.028 · Odds ratio (or): 1.61 · 95% CI 1.05 to 2.45
SecondaryChange From Baseline in Fasting Serum Glucose (FSG)

FSG is a test to determine sugar levels in serum sample after an overnight fast. LS mean was determined by MMRM model with Baseline + Baseline HbA1c (High, Low) Group, OAM-based + Pre-study OAM Group 1 + Treatment + Time + Treatment\*Time as variables.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · milligrams per deciliter (mg/dL)
Change From Baseline in Fasting Serum Glucose (FSG)
milligrams per deciliter (mg/dL)Dulaglutide 1.5 mgDulaglutide 0.75 mg
Change From Baseline in Fasting Serum Glucose (FSG)-42.4 ± 1.47-33.1 ± 2.09
Statistical analysis
  • Dulaglutide 1.5 mg vs Dulaglutide 0.75 mg · Mixed Models Analysis · p = <.001 · Ls mean difference: -9.4 · 95% CI -14.4 to -4.3
SecondaryChange From Baseline in 6-point Self-Monitored Blood Glucose (SMBG)

SMBG 6-point profiles were measured at morning (premeal-fasting, 2-hour post meal), midday (premeal, 2-hour post meal), and evening (premeal, 2-hour post meal). LS mean was determined by analysis of covariance (ANCOVA) model with Baseline + Baseline HbA1c (High, Low) Group, OAM-based + Pre-study OAM Group 1 + Treatment as variables.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · mg/dL
Change From Baseline in 6-point Self-Monitored Blood Glucose (SMBG)
mg/dLDulaglutide 1.5 mgDulaglutide 0.75 mg
Morning premeal-fasting-45.6 ± 1.33-38.4 ± 1.86
Morning 2-hour post meal-70.6 ± 2.42-60.5 ± 3.39
Midday premeal-55.3 ± 1.77-47.0 ± 2.47
Midday 2-hour post meal-73.7 ± 2.37-61.2 ± 3.32
Evening premeal-50.3 ± 1.60-46.4 ± 2.24
Evening 2-hour post meal-61.1 ± 2.27-49.8 ± 3.18
Statistical analysis
  • Dulaglutide 1.5 mg vs Dulaglutide 0.75 mg · ANCOVA · p = 0.002 · Ls mean difference: -7.2 · 95% CI -11.7 to -2.7
  • Dulaglutide 1.5 mg vs Dulaglutide 0.75 mg · ANCOVA · p = 0.016 · Ls mean difference: -10.1 · 95% CI -18.3 to -1.9
  • Dulaglutide 1.5 mg vs Dulaglutide 0.75 mg · ANCOVA · p = 0.007 · Ls mean difference: -8.3 · 95% CI -14.2 to -2.3
  • Dulaglutide 1.5 mg vs Dulaglutide 0.75 mg · ANCOVA · p = 0.002 · Ls mean difference: -12.5 · 95% CI -20.5 to -4.5
  • Dulaglutide 1.5 mg vs Dulaglutide 0.75 mg · ANCOVA · p = 0.158 · Ls mean difference: -3.9 · 95% CI -9.3 to 1.5
  • Dulaglutide 1.5 mg vs Dulaglutide 0.75 mg · ANCOVA · p = 0.004 · Ls mean difference: -11.3 · 95% CI -19.0 to -3.7
SecondaryChange From Baseline in Body Weight

LS mean was determined by MMRM model with Baseline + Baseline HbA1c (High, Low) Group, OAM-based + Pre-study OAM Group 1 + Treatment + Time + Treatment\*Time as variables.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · kilogram (kg)
Change From Baseline in Body Weight
kilogram (kg)Dulaglutide 1.5 mgDulaglutide 0.75 mg
Change From Baseline in Body Weight-0.5 ± 0.14-0.2 ± 0.19
Statistical analysis
  • Dulaglutide 1.5 mg vs Dulaglutide 0.75 mg · Mixed Models Analysis · p = 0.213 · Ls mean difference: -0.3 · 95% CI -0.8 to 0.2

Adverse events

Collected over Baseline to Week 56.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dulaglutide 1.5 mg1/391 (0.3%)15/391 (3.8%)298/391 (76.2%)
Dulaglutide 0.75 mg0/195 (0%)7/195 (3.6%)143/195 (73.3%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventDulaglutide 1.5 mgDulaglutide 0.75 mg
Cervix carcinoma stage 0Neoplasms benign, malignant and unspecified (incl cysts and polyps)1/1130/53
Angina pectorisCardiac disorders0/3911/195
Retinal haemorrhageEye disorders0/3911/195
Vitreous haemorrhageEye disorders0/3911/195
Colitis ischaemicGastrointestinal disorders0/3911/195
Gastric ulcer haemorrhageGastrointestinal disorders0/3911/195
Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3911/195
Renal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3911/195
Acute myocardial infarctionCardiac disorders1/3910/195
Cardiac failure congestiveCardiac disorders1/3910/195
Most frequent other events
Showing 10 of 360
Most frequent other events
EventDulaglutide 1.5 mgDulaglutide 0.75 mg
ConstipationGastrointestinal disorders49/39117/195
DiarrhoeaGastrointestinal disorders40/39116/195
PyrexiaGeneral disorders39/39114/195
NauseaGastrointestinal disorders35/3919/195
NasopharyngitisInfections and infestations22/39117/195
Covid-19Infections and infestations30/39116/195
Abdominal discomfortGastrointestinal disorders24/3915/195
Coronavirus infectionInfections and infestations18/3918/195
HyperglycaemiaMetabolism and nutrition disorders7/3918/195
ArthralgiaMusculoskeletal and connective tissue disorders9/3918/195

Baseline characteristics

All randomly assigned participants, excluding the GCP compliance investigative site, who were exposed to at least 1 dose of study intervention.

Age, Continuous
Age, Continuous(years)Dulaglutide 1.5 mgDulaglutide 0.75 mgTotal
Mean60.10 ± 10.7060.70 ± 10.7460.30 ± 10.71
Sex: Female, Male
Sex: Female, Male(Participants)Dulaglutide 1.5 mgDulaglutide 0.75 mgTotal
Female11353166
Male278142420
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dulaglutide 1.5 mgDulaglutide 0.75 mgTotal
American Indian or Alaska Native000
Asian391195586
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Dulaglutide 1.5 mgDulaglutide 0.75 mgTotal
Japan391195586
Hemoglobin A1c (HbA1c)
Hemoglobin A1c (HbA1c)(Percentage of HbA1c)Dulaglutide 1.5 mgDulaglutide 0.75 mgTotal
Mean8.61 ± 0.628.61 ± 0.608.61 ± 0.61
09

Study locations

44 sites
  • Tosaki Clinic for Diabetes and Endocrinology
    Nagoya-shi, Aichi 468-0009, Japan
  • Nakayama Clinic
    Nagoya, Aichi 456-0058, Japan
  • Kashiwa City Hospital
    Kashiwa, Chiba 277-0825, Japan
  • Kobari General Clinic
    Noda, Chiba 278-0004, Japan
  • Nippon Kokan Fukuyama Hospital
    Fukuyama-shi, Hiroshima 721-0927, Japan
  • Yamagata Naika Clinic
    Asahikawa, Hokkaido 078-8234, Japan
  • Hasegawa Medical Clinic
    Chitose, Hokkaido 066-0032, Japan
  • Yuri Ono Clinic
    Sapporo, Hokkaido 060-0001, Japan
  • Manda Memorial Hospital
    Sapporo, Hokkaido 060-0062, Japan
  • Miyanosawa Clinic of Internal Medicine and Cardiology
    Sapporo, Hokkaido 063-0826, Japan
  • Takabe Diabetes Clinic
    Himeji, Hyogo 670-0837, Japan
  • Nakamoto Internal Medicine Clinic
    Mito, Ibaraki 310-0826, Japan
  • Nakakinen clinic
    Naka, Ibaraki 311-0113, Japan
  • Nishiyamadou Keiwa Hospital
    Naka, Ibaraki 311-0133, Japan
  • Hayashi Diabetes Internal Medicine Clinic
    Chigasaki, Kanagawa 253-0044, Japan
  • Takai Internal Medicine Clinic
    Kamakura-shi, Kanagawa 247-0056, Japan
  • Shonan Takai Clinic
    Kamakura, Kanagawa 247-0055, Japan
  • Yamagishi Clinic Sagamiono
    Sagamihara, Kanagawa 252-0303, Japan
  • Medical Corporation Yuga Tsuruma Kaneshiro Diabetes Clinic
    Yamato-shi, Kanagawa 242-0004, Japan
  • Seiryo Internal Medicine
    Iwanuma, Miyagi 989-2451, Japan
  • Gibo Hepatology Clinic
    Matsumoto, Nagano 399-0036, Japan
  • Shiraiwa Medical Clinic
    Kashiwara, Osaka 582-0005, Japan
  • Medical Corporation Heishinkai OCROM Clinic
    Suita-shi, Osaka 565-0853, Japan
  • Sugiura Internal Medicine Clinic
    Soka, Saitama 340-0034, Japan
  • Seiwa Clinic
    Adachi-ku, Tokyo 120-0011, Japan
  • Tokyo-Eki Center-building Clinic
    Chuo-ku, Tokyo 103-0027, Japan
  • Medical Corporation Chiseikai Tokyo Center Clinic
    Chuo-ku, Tokyo 103-0028, Japan
  • Fukuwa Clinic
    Chuo-ku, Tokyo 104-0031, Japan
  • Hachioji Diabetes Clinic
    Hachioji, Tokyo 192-0083, Japan
  • Minamino Cardiovascular Hospital
    Hachioji, Tokyo 192-0918, Japan
  • Nomura Clinic
    Itabashi, Tokyo 173-0004, Japan
  • Yutenji Medical Clinic
    Meguro-ku, Tokyo 153-0053, Japan
  • Kanno Naika
    Mitaka, Tokyo 181-0013, Japan
  • Heishinkai Medical Group ToCROM Clinic
    Shinjuku-ku, Tokyo 160-0008, Japan
  • Futata Tetsuhiro Clinic
    Fukuoka, 810-0006, Japan
  • Yoshimura Clinic
    Kumamoto, 861-8039, Japan
  • Jinnouchi Hospital
    Kumamoto, 862-0976, Japan
  • Heiwadai Hospital
    Miyazaki, 880-0034, Japan
  • Ota Diabetes Internal Medicine Clinic
    Nagano, 380-0802, Japan
  • Abe Clinic
    Oita, 870-0039, Japan
  • AMC Nishiumeda Clinic
    Osaka, 530-0001, Japan
  • Kitada Clinic
    Osaka, 538-0044, Japan
  • Osaka Metropolitan Univ Hosp
    Osaka, 545-8586, Japan
  • Nanko Clinic
    Osaka, 559-0011, Japan
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Oct 2022, 17 months.

Results were first posted in Sep 2023, 11 months after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 17 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2021
First posted
Mar 22, 2021
StartActual
Apr 13, 2021
Primary completionActual
Oct 1, 2022
CompletionActual
Apr 26, 2023
Results first posted
Sep 21, 2023
Last update
May 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT04809220
Responsible party
Sponsor
First posted
Mar 22, 2021
Start date
Apr 13, 2021
Primary completion
Oct 1, 2022
Completion
Apr 26, 2023
Results posted
Sep 21, 2023
Last update
May 22, 2024

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon- Fri 9 AM- 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dulaglutide

Start the discussion